Form 4: OCULAR THERAPEUTIX CMO Sells Shares for Tax Obligations

Ocular Therapeutix's Chief Medical Officer, Nadia Waheed, sold 3,510 shares of common stock at a weighted average price of $7.74 to cover tax withholding obligations.

Summary

• Nadia Waheed, Chief Medical Officer of Ocular Therapeutix, Inc. (OCUL), sold 3,510 shares of common stock.
• The transaction occurred on February 20, 2026, at a weighted average price of $7.74 per share.
• The shares were sold to satisfy tax withholding obligations in connection with the vesting of restricted stock units on February 11, 2026.
• This sale was executed pursuant to a Rule 10b5-1(c) plan adopted by Ms. Waheed on June 1, 2024, and does not represent a discretionary trade.
• Following this transaction, Ms. Waheed beneficially owns 314,907 shares of Ocular Therapeutix common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. It is a routine, non-discretionary transaction for tax purposes and does not reflect a change in the insider's investment sentiment or the company's operational performance.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• The sales do not represent a discretionary trade by the reporting person.
• The transaction represents shares of common stock sold pursuant to a durable automatic sale instruction adopted on June 1, 2024, to effect the sell-to-cover election for tax withholding obligations related to RSU vesting on February 11, 2026.

Industry Context

StockSavvy.ai notes that 'sell-to-cover' transactions by corporate insiders are a common and routine practice to manage tax liabilities arising from the vesting of equity awards like restricted stock units. These sales are typically pre-scheduled under Rule 10b5-1 plans and are generally not indicative of an insider's discretionary view on the company's future prospects.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary transaction for tax purposes and does not signal a change in company fundamentals or insider confidence.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary 'sell-to-cover' transaction by a corporate officer to satisfy tax obligations related to RSU vesting. Such transactions, executed under a pre-established 10b5-1 plan, do not provide new material information regarding the company's operational performance or the insider's discretionary view on the stock's future. Therefore, it does not warrant a change in investment thesis, and a 'hold' recommendation is appropriate.

Keywords

Ocular Therapeutix, OCUL, Insider Trading, Form 4, Stock Sale, Chief Medical Officer, Nadia Waheed, Rule 10b5-1, Tax Withholding, Restricted Stock Units